A whole exome sequencing study has identified specific genetic variants that may accelerate breast cancer development in women carrying pathogenic BRCA1 mutations. The research found that damaging variants in genes involved in innate immunity are significantly associated with earlier breast cancer onset in this high-risk population.
The study focused on genes related to natural killer (NK) cell activation, a critical component of the body's innate immune response. Women with BRCA1 mutations who also carried damaging variants in these immune response genes experienced breast cancer onset at younger ages compared to those without such variants.